XML 118 R96.htm IDEA: XBRL DOCUMENT v3.23.3
Collaborative and Other Relationships - Samsung Bioepis (Details)
$ in Millions
1 Months Ended 3 Months Ended 9 Months Ended
Dec. 31, 2019
product
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
Collaborative arrangements and non-collaborative arrangement transactions            
Collaboration profit sharing/(loss reimbursement)   $ 50.5 $ 45.3 $ 164.5 $ (42.6)  
Samsung Bioepis            
Collaborative arrangements and non-collaborative arrangement transactions            
Collaboration profit sharing/(loss reimbursement)   56.4 $ 48.7 $ 170.4 $ 171.4  
Samsung Bioepis            
Collaborative arrangements and non-collaborative arrangement transactions            
Contingent Commercialized Rights, Number Of Products | product 2          
Expected profit share percentage 45.00%     50.00%    
Estimated additional payments upon achievement of development and commercial milestones       $ 180.0    
Collaboration agreement term       5 years    
Option exercise fee       $ 60.0    
Samsung Bioepis | Related Party            
Collaborative arrangements and non-collaborative arrangement transactions            
Accounts receivable   13.0   13.0   $ 2.0
Accounts payable   $ 81.6   $ 81.6   $ 40.5